Table 1.
Patient clinical parameters.
| Clinical parameters | Patients (n = 91) | |
|---|---|---|
| Gender, n (%) | Male | 60 (66) |
| Female | 31 (34) | |
| Age, median | 68 (45–83) | |
| BMI, median | 26 (15–45) | |
| ASA score, n (%) | Not discriminated | 11 (12) |
| I | 2 (2) | |
| II | 56 (62) | |
| III | 21 (23) | |
| IV | 1 (1) | |
| Grade | G1/G2 | 85 (93) |
| G3/G4 | 6 (7) | |
| Location (%) | 1/3 superior | 19 (21) |
| 1/3 medium | 28 (31) | |
| 1/3 inferior | 44 (48) | |
| Tumor extension (mm), median | 58 (5–120) | |
| Distance to anal verge (mm), median | 60 (0–130) | |
| cT | 1 | 1 (1) |
| 2 | 10 (11) | |
| 3 | 64 (70) | |
| 4 | 16 (18) | |
| cN | 0 | 9 (10) |
| + | 82 (90) | |
| cM | 0 | 78 (86) |
| 1 | 13 (14) | |
| CRM, n (%) | Free | 67 (74) |
| Threatened or invaded | 24 (26) | |
| EMVI, n (%) | Negative | 86 (95) |
| Present | 5 (5) | |
| c Stage, n (%) | I | 3 (3) |
| II | 8 (9) | |
| III | 68 (75) | |
| IV | 12 (13) | |
| CEA (mg/mL) | 1.9 (0.5–163) | |
| Chemotherapy | Capecitabine based | 83 (91) |
| 5-FU based | 8 (9) | |
| TRG (CAP), n (%) | 0 | 15 (17) |
| 1 | 24 (26) | |
| 2 | 33 (36) | |
| 3 | 19 (21) |
BMI, Body Mass Index; ASA, American Society of Anaesthesiologists; CRM, circumferential resection margin; EMVI, extramural vascular invasion; CEA, carcinoembrinonary antigen; TRG, tumor regression grade; CAP, College of American Pathologists.